Dinaciclib: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|A cyclin-dependent kinase inhibitor used in cancer treatment}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| IUPAC_name = 2-[[3-[[2-[(aminocarbonyl)amino]ethyl]amino]-1H-indol-7-yl]oxy]-N-(5-quinolinylmethyl)benzamide | |||
| image = Dinaciclib.svg | |||
| width = 200px | |||
}} | |||
'''Dinaciclib''' is a small molecule inhibitor of [[cyclin-dependent kinases]] (CDKs), which are enzymes that play a crucial role in the regulation of the [[cell cycle]]. It is primarily investigated for its potential use in the treatment of various types of [[cancer]]. | |||
Dinaciclib | ==Mechanism of Action== | ||
Dinaciclib functions by inhibiting the activity of CDKs, particularly CDK1, CDK2, CDK5, and CDK9. These kinases are essential for the progression of the cell cycle and the transcription of genes necessary for cell proliferation. By inhibiting these kinases, dinaciclib can induce cell cycle arrest and promote [[apoptosis]] in cancer cells. | |||
== Clinical | ==Clinical Development== | ||
Dinaciclib has been evaluated in several [[clinical trials]] for its efficacy and safety in treating different cancers, including [[leukemia]], [[breast cancer]], and [[lung cancer]]. The drug has shown promise in preclinical studies and early-phase clinical trials, demonstrating the ability to reduce tumor growth and enhance the effects of other anticancer agents. | |||
==Pharmacokinetics== | |||
The pharmacokinetic profile of dinaciclib involves its absorption, distribution, metabolism, and excretion. It is administered intravenously, and its distribution in the body is characterized by a rapid clearance and a relatively short half-life. The metabolism of dinaciclib is primarily hepatic, and it is excreted through both renal and fecal pathways. | |||
== Side Effects == | ==Side Effects== | ||
Common side effects associated with dinaciclib include [[neutropenia]], [[thrombocytopenia]], [[anemia]], and gastrointestinal symptoms such as [[nausea]] and [[vomiting]]. These side effects are consistent with the drug's mechanism of action, as it affects rapidly dividing cells, including those in the bone marrow and gastrointestinal tract. | |||
==Research and Future Directions== | |||
Ongoing research is focused on optimizing the use of dinaciclib in combination with other therapeutic agents to enhance its anticancer efficacy. Studies are also exploring its potential role in overcoming resistance to other treatments and its application in a broader range of cancer types. | |||
== Future | |||
==Related Pages== | |||
* [[Cyclin-dependent kinase]] | * [[Cyclin-dependent kinase]] | ||
* [[Cell cycle]] | |||
* [[Apoptosis]] | |||
* [[Cancer treatment]] | * [[Cancer treatment]] | ||
[[Category:Antineoplastic drugs]] | |||
[[Category:Cyclin-dependent kinase inhibitors]] | |||
<gallery> | |||
File:Dinaciclib.svg|Dinaciclib | |||
</gallery> | |||
Latest revision as of 01:38, 20 February 2025
A cyclin-dependent kinase inhibitor used in cancer treatment
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = 2-[[3-[[2-[(aminocarbonyl)amino]ethyl]amino]-1H-indol-7-yl]oxy]-N-(5-quinolinylmethyl)benzamide
| image = Dinaciclib.svg
| width = 200px
}}
Dinaciclib is a small molecule inhibitor of cyclin-dependent kinases (CDKs), which are enzymes that play a crucial role in the regulation of the cell cycle. It is primarily investigated for its potential use in the treatment of various types of cancer.
Mechanism of Action[edit]
Dinaciclib functions by inhibiting the activity of CDKs, particularly CDK1, CDK2, CDK5, and CDK9. These kinases are essential for the progression of the cell cycle and the transcription of genes necessary for cell proliferation. By inhibiting these kinases, dinaciclib can induce cell cycle arrest and promote apoptosis in cancer cells.
Clinical Development[edit]
Dinaciclib has been evaluated in several clinical trials for its efficacy and safety in treating different cancers, including leukemia, breast cancer, and lung cancer. The drug has shown promise in preclinical studies and early-phase clinical trials, demonstrating the ability to reduce tumor growth and enhance the effects of other anticancer agents.
Pharmacokinetics[edit]
The pharmacokinetic profile of dinaciclib involves its absorption, distribution, metabolism, and excretion. It is administered intravenously, and its distribution in the body is characterized by a rapid clearance and a relatively short half-life. The metabolism of dinaciclib is primarily hepatic, and it is excreted through both renal and fecal pathways.
Side Effects[edit]
Common side effects associated with dinaciclib include neutropenia, thrombocytopenia, anemia, and gastrointestinal symptoms such as nausea and vomiting. These side effects are consistent with the drug's mechanism of action, as it affects rapidly dividing cells, including those in the bone marrow and gastrointestinal tract.
Research and Future Directions[edit]
Ongoing research is focused on optimizing the use of dinaciclib in combination with other therapeutic agents to enhance its anticancer efficacy. Studies are also exploring its potential role in overcoming resistance to other treatments and its application in a broader range of cancer types.
Related Pages[edit]
-
Dinaciclib
